Dr. Reddy’s Q4 Net Profit Rises 22% YoY to ₹1,594 Crore; Revenue Up 20%

Hyderabad-headquartered pharmaceutical giant Dr. Reddy’s Laboratories has announced Q4 FY24 results.

Dr. Reddy’s Q4 FY25 performance

• Net profit: Reddy’s reported ₹1,594 crore of net profit for the Q4 FY 25. This is up by a year-on-year increase of 22% from ₹1,307 crore Q4 FY 24.
• Revenue: It increased by 20% year-on-year to ₹8,506 crore driven by robust growth in core markets such as Europe and India.
• EBITDA: Quarterly EBITDA improved by 32% year on year to ₹2,470 crore and was better on a margin basis at 29.1%, 26.2% versus last.

Final Dividend:

Final equity share dividend of ₹8 per equity share as approved by the Directors during the Financial year FY25.

Stock Performance:

Shares of Dr. Reddy’s Pharma have witnessed a marginal 1.07% increase in the last year, and a 3.42% gain in the last month. The shares of Dr. Reddy’s have fallen by 12% YTD and are marginally weaker than the Nifty Pharma index, which has fallen by 10.06% over the corresponding period.